Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells

Karen Anderson, Wanyong Zeng, Tetsuro Sasada, Jaewon Choi, Angelika B. Riemer, Mei Su, Donna Drakoulakos, Yoon Joong Kang, Vladimir Brusic, Catherine Wu, Ellis L. Reinherz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Professional APCs, such as dendritic cells, are routinely used in vitro for the generation of cytotoxic T lymphocytes specific for tumor antigens. In addition to dendritic cells, CD40-activated B cells and variant K562 leukemic cells can be readily transfected with nucleic acids for in vitro and in vivo antigen presentation. However, the expression of immunoproteasome components in dendritic cells may preclude display of tumor antigens such as Mart1/MelanA. Here, we use three target epitopes, two derived from tumor antigens [Mart1 26-34 (M26) and Cyp1B1239-247 (Cyp239)] and one derived from the influenza A viral antigen [FluM158-66 (FluM58)], to demonstrate that CD40-activated B cells, like dendritic cells, have a limited capability to process certain tumor antigens. In contrast, the K562 HLA-A*0201 transfectant efficiently processes and presents M26 and Cyp239 as well as the influenza FluM58 epitopes to T cells. These results demonstrate that the choice of target APC for gene transfer of tumor antigens may be limited by the relative efficacy of proteasome components to process certain tumor epitopes. Importantly, K562 can be exploited as an artificial APC, efficient in processing both M26 and Cyp239 epitopes and presumably, by extension, other relevant tumor antigens.

Original languageEnglish (US)
Pages (from-to)857-867
Number of pages11
JournalCancer Immunology, Immunotherapy
Volume60
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Antigen Presentation
Neoplasm Antigens
Dendritic Cells
B-Lymphocytes
Epitopes
Human Influenza
MART-1 Antigen
APC Genes
T-Lymphocyte Epitopes
K562 Cells
Viral Antigens
Cytotoxic T-Lymphocytes
Proteasome Endopeptidase Complex
Nucleic Acids
Neoplasms

Keywords

  • Antigen processing
  • Dendritic cells
  • Tumor immunity
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. / Anderson, Karen; Zeng, Wanyong; Sasada, Tetsuro; Choi, Jaewon; Riemer, Angelika B.; Su, Mei; Drakoulakos, Donna; Kang, Yoon Joong; Brusic, Vladimir; Wu, Catherine; Reinherz, Ellis L.

In: Cancer Immunology, Immunotherapy, Vol. 60, No. 6, 06.2011, p. 857-867.

Research output: Contribution to journalArticle

Anderson, K, Zeng, W, Sasada, T, Choi, J, Riemer, AB, Su, M, Drakoulakos, D, Kang, YJ, Brusic, V, Wu, C & Reinherz, EL 2011, 'Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells', Cancer Immunology, Immunotherapy, vol. 60, no. 6, pp. 857-867. https://doi.org/10.1007/s00262-011-0995-5
Anderson, Karen ; Zeng, Wanyong ; Sasada, Tetsuro ; Choi, Jaewon ; Riemer, Angelika B. ; Su, Mei ; Drakoulakos, Donna ; Kang, Yoon Joong ; Brusic, Vladimir ; Wu, Catherine ; Reinherz, Ellis L. / Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. In: Cancer Immunology, Immunotherapy. 2011 ; Vol. 60, No. 6. pp. 857-867.
@article{9d38a4f5b8a64b92b942e2fcb3c7ba76,
title = "Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells",
abstract = "Professional APCs, such as dendritic cells, are routinely used in vitro for the generation of cytotoxic T lymphocytes specific for tumor antigens. In addition to dendritic cells, CD40-activated B cells and variant K562 leukemic cells can be readily transfected with nucleic acids for in vitro and in vivo antigen presentation. However, the expression of immunoproteasome components in dendritic cells may preclude display of tumor antigens such as Mart1/MelanA. Here, we use three target epitopes, two derived from tumor antigens [Mart1 26-34 (M26) and Cyp1B1239-247 (Cyp239)] and one derived from the influenza A viral antigen [FluM158-66 (FluM58)], to demonstrate that CD40-activated B cells, like dendritic cells, have a limited capability to process certain tumor antigens. In contrast, the K562 HLA-A*0201 transfectant efficiently processes and presents M26 and Cyp239 as well as the influenza FluM58 epitopes to T cells. These results demonstrate that the choice of target APC for gene transfer of tumor antigens may be limited by the relative efficacy of proteasome components to process certain tumor epitopes. Importantly, K562 can be exploited as an artificial APC, efficient in processing both M26 and Cyp239 epitopes and presumably, by extension, other relevant tumor antigens.",
keywords = "Antigen processing, Dendritic cells, Tumor immunity, Vaccination",
author = "Karen Anderson and Wanyong Zeng and Tetsuro Sasada and Jaewon Choi and Riemer, {Angelika B.} and Mei Su and Donna Drakoulakos and Kang, {Yoon Joong} and Vladimir Brusic and Catherine Wu and Reinherz, {Ellis L.}",
year = "2011",
month = "6",
doi = "10.1007/s00262-011-0995-5",
language = "English (US)",
volume = "60",
pages = "857--867",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells

AU - Anderson, Karen

AU - Zeng, Wanyong

AU - Sasada, Tetsuro

AU - Choi, Jaewon

AU - Riemer, Angelika B.

AU - Su, Mei

AU - Drakoulakos, Donna

AU - Kang, Yoon Joong

AU - Brusic, Vladimir

AU - Wu, Catherine

AU - Reinherz, Ellis L.

PY - 2011/6

Y1 - 2011/6

N2 - Professional APCs, such as dendritic cells, are routinely used in vitro for the generation of cytotoxic T lymphocytes specific for tumor antigens. In addition to dendritic cells, CD40-activated B cells and variant K562 leukemic cells can be readily transfected with nucleic acids for in vitro and in vivo antigen presentation. However, the expression of immunoproteasome components in dendritic cells may preclude display of tumor antigens such as Mart1/MelanA. Here, we use three target epitopes, two derived from tumor antigens [Mart1 26-34 (M26) and Cyp1B1239-247 (Cyp239)] and one derived from the influenza A viral antigen [FluM158-66 (FluM58)], to demonstrate that CD40-activated B cells, like dendritic cells, have a limited capability to process certain tumor antigens. In contrast, the K562 HLA-A*0201 transfectant efficiently processes and presents M26 and Cyp239 as well as the influenza FluM58 epitopes to T cells. These results demonstrate that the choice of target APC for gene transfer of tumor antigens may be limited by the relative efficacy of proteasome components to process certain tumor epitopes. Importantly, K562 can be exploited as an artificial APC, efficient in processing both M26 and Cyp239 epitopes and presumably, by extension, other relevant tumor antigens.

AB - Professional APCs, such as dendritic cells, are routinely used in vitro for the generation of cytotoxic T lymphocytes specific for tumor antigens. In addition to dendritic cells, CD40-activated B cells and variant K562 leukemic cells can be readily transfected with nucleic acids for in vitro and in vivo antigen presentation. However, the expression of immunoproteasome components in dendritic cells may preclude display of tumor antigens such as Mart1/MelanA. Here, we use three target epitopes, two derived from tumor antigens [Mart1 26-34 (M26) and Cyp1B1239-247 (Cyp239)] and one derived from the influenza A viral antigen [FluM158-66 (FluM58)], to demonstrate that CD40-activated B cells, like dendritic cells, have a limited capability to process certain tumor antigens. In contrast, the K562 HLA-A*0201 transfectant efficiently processes and presents M26 and Cyp239 as well as the influenza FluM58 epitopes to T cells. These results demonstrate that the choice of target APC for gene transfer of tumor antigens may be limited by the relative efficacy of proteasome components to process certain tumor epitopes. Importantly, K562 can be exploited as an artificial APC, efficient in processing both M26 and Cyp239 epitopes and presumably, by extension, other relevant tumor antigens.

KW - Antigen processing

KW - Dendritic cells

KW - Tumor immunity

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=79959754730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959754730&partnerID=8YFLogxK

U2 - 10.1007/s00262-011-0995-5

DO - 10.1007/s00262-011-0995-5

M3 - Article

VL - 60

SP - 857

EP - 867

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -